Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Non-Current Deffered Revenue: 2009-2010

  • Cumberland Pharmaceuticals' Non-Current Deffered Revenue rose 231.98% to $558.0 billion in Q4 2010 from the same period last year, while for Dec 2010 it was $558.0 billion, marking a year-over-year increase of 231.98%. This contributed to the annual value of $558.0 billion for FY2010, which is 231.98% up from last year.
  • As of Q4 2010, Cumberland Pharmaceuticals' Non-Current Deffered Revenue stood at $558.0 billion, which was up 231.98% from $168.1 billion recorded in Q4 2009.
  • Over the past 5 years, Cumberland Pharmaceuticals' Non-Current Deffered Revenue peaked at $558.0 billion during Q4 2010, and registered a low of $168.1 billion during Q4 2009.
  • For the 2-year period, Cumberland Pharmaceuticals' Non-Current Deffered Revenue averaged around $363.1 billion, with its median value being $363.1 billion (2009).
  • Data for Cumberland Pharmaceuticals' Non-Current Deffered Revenue shows a peak YoY skyrocketed of 231.98% (in 2010) over the last 5 years.
  • Over the past 2 years, Cumberland Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $168.1 billion in 2009, then surged by 231.98% to $558.0 billion in 2010.